|Bid||0.3820 x 900|
|Ask||0.3900 x 1800|
|Day's Range||0.3811 - 0.4298|
|52 Week Range||0.3260 - 5.5900|
|Beta (5Y Monthly)||0.70|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 06, 2023 - Nov 10, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for FREQ
LEXINGTON, Mass., August 10, 2023--Frequency Therapeutics, Inc. (Nasdaq: FREQ) today announced business updates and financial results for the second quarter ended June 30, 2023.
Post-merger, Frequency (FREQ) focuses on advancing RNA editing programs. This combined entity is set to operate under the name Korro Bio, which will apply to trade on the NASDAQ under the ticker symbol KRRO.
Korro Bio Inc and Frequency Therapeutics Inc (NASDAQ: FREQ) announced an all-stock merger transaction. Under the merger agreement's terms, stockholders of Korro Bio will receive newly issued shares of Frequency Therapeutics. Frequency Therapeutics has discontinued developing its remyelination program for Multiple Sclerosis as it explores strategic alternatives for the program. Suppose Frequency Therapeutics has not otherwise monetized its remyelination program before the closing of the proposed